Boron neutron capture therapy (BNCT)

Implications of neutron beam and boron compound characteristics

Floyd Wheeler, David Nigg, Jacek Capala, Peter Watkins, Corine Vroegindeweij, Iiro Auterinen, Tiina Seppälä, Darren Bleuel

Research output: Contribution to journalArticleScientificpeer-review

42 Citations (Scopus)

Abstract

The potential efficacy of boron neutron capture therapy (BNCT) for malignant glioma is a significant function of epithermal‐neutron beam biophysical characteristics as well as boron compound biodistribution characteristics. Monte Carlo analyses were performed to evaluate the relative significance of these factors on theoretical tumor control using a standard model. The existing, well‐characterized epithermal‐neutron sources at the Brookhaven Medical Research Reactor (BMRR), the Petten High Flux Reactor (HFR), and the Finnish Research Reactor (FiR‐1) were compared. Results for a realistic accelerator design by the E. O. Lawrence Berkeley National Laboratory (LBL) are also compared. Also the characteristics of the compound p‐Boronophenylaline Fructose (BPA‐F) and a hypothetical next‐generation compound were used in a comparison of the BMRR and a hypothetical improved reactor. All components of dose induced by an external epithermal‐neutron beam fall off quite rapidly with depth in tissue. Delivery of dose to greater depths is limited by the healthy‐tissue tolerance and a reduction in the hydrogen‐recoil and incident gamma dose allow for longer irradiation and greater dose at a depth. Dose at depth can also be increased with a beam that has higher neutron energy (without too high a recoil dose) and a more forward peaked angular distribution. Of the existing facilities, the FiR‐1 beam has the better quality (lower hydrogen‐recoil and incident gamma dose) and a penetrating neutron spectrum and was found to deliver a higher value of Tumor Control Probability (TCP) than other existing beams at shallow depth. The greater forwardness and penetration of the HFR the FiR‐1 at greater depths. The hypothetical reactor and accelerator beams outperform at both shallow and greater depths. In all cases, the hypothetical compound provides a significant improvement in efficacy but it is shown that the full benefit of improved compound is not realized until the neutron beam is fully optimized.
Original languageEnglish
Pages (from-to)1237-1244
Number of pages8
JournalMedical Physics
Volume26
Issue number7
DOIs
Publication statusPublished - 1999
MoE publication typeA1 Journal article-refereed

Fingerprint

Boron Compounds
Boron Neutron Capture Therapy
Neutrons
Biomedical Research
Fructose
Glioma
Neoplasms
Research

Keywords

  • BNCT neutron
  • glioma
  • treatment planning

Cite this

Wheeler, F., Nigg, D., Capala, J., Watkins, P., Vroegindeweij, C., Auterinen, I., ... Bleuel, D. (1999). Boron neutron capture therapy (BNCT): Implications of neutron beam and boron compound characteristics. Medical Physics, 26(7), 1237-1244. https://doi.org/10.1118/1.598618
Wheeler, Floyd ; Nigg, David ; Capala, Jacek ; Watkins, Peter ; Vroegindeweij, Corine ; Auterinen, Iiro ; Seppälä, Tiina ; Bleuel, Darren. / Boron neutron capture therapy (BNCT) : Implications of neutron beam and boron compound characteristics. In: Medical Physics. 1999 ; Vol. 26, No. 7. pp. 1237-1244.
@article{685b72eab36e4a2785ee1d2ee68eabf0,
title = "Boron neutron capture therapy (BNCT): Implications of neutron beam and boron compound characteristics",
abstract = "The potential efficacy of boron neutron capture therapy (BNCT) for malignant glioma is a significant function of epithermal‐neutron beam biophysical characteristics as well as boron compound biodistribution characteristics. Monte Carlo analyses were performed to evaluate the relative significance of these factors on theoretical tumor control using a standard model. The existing, well‐characterized epithermal‐neutron sources at the Brookhaven Medical Research Reactor (BMRR), the Petten High Flux Reactor (HFR), and the Finnish Research Reactor (FiR‐1) were compared. Results for a realistic accelerator design by the E. O. Lawrence Berkeley National Laboratory (LBL) are also compared. Also the characteristics of the compound p‐Boronophenylaline Fructose (BPA‐F) and a hypothetical next‐generation compound were used in a comparison of the BMRR and a hypothetical improved reactor. All components of dose induced by an external epithermal‐neutron beam fall off quite rapidly with depth in tissue. Delivery of dose to greater depths is limited by the healthy‐tissue tolerance and a reduction in the hydrogen‐recoil and incident gamma dose allow for longer irradiation and greater dose at a depth. Dose at depth can also be increased with a beam that has higher neutron energy (without too high a recoil dose) and a more forward peaked angular distribution. Of the existing facilities, the FiR‐1 beam has the better quality (lower hydrogen‐recoil and incident gamma dose) and a penetrating neutron spectrum and was found to deliver a higher value of Tumor Control Probability (TCP) than other existing beams at shallow depth. The greater forwardness and penetration of the HFR the FiR‐1 at greater depths. The hypothetical reactor and accelerator beams outperform at both shallow and greater depths. In all cases, the hypothetical compound provides a significant improvement in efficacy but it is shown that the full benefit of improved compound is not realized until the neutron beam is fully optimized.",
keywords = "BNCT neutron, glioma, treatment planning",
author = "Floyd Wheeler and David Nigg and Jacek Capala and Peter Watkins and Corine Vroegindeweij and Iiro Auterinen and Tiina Sepp{\"a}l{\"a} and Darren Bleuel",
year = "1999",
doi = "10.1118/1.598618",
language = "English",
volume = "26",
pages = "1237--1244",
journal = "Medical Physics",
issn = "0094-2405",
number = "7",

}

Wheeler, F, Nigg, D, Capala, J, Watkins, P, Vroegindeweij, C, Auterinen, I, Seppälä, T & Bleuel, D 1999, 'Boron neutron capture therapy (BNCT): Implications of neutron beam and boron compound characteristics', Medical Physics, vol. 26, no. 7, pp. 1237-1244. https://doi.org/10.1118/1.598618

Boron neutron capture therapy (BNCT) : Implications of neutron beam and boron compound characteristics. / Wheeler, Floyd; Nigg, David; Capala, Jacek; Watkins, Peter; Vroegindeweij, Corine; Auterinen, Iiro; Seppälä, Tiina; Bleuel, Darren.

In: Medical Physics, Vol. 26, No. 7, 1999, p. 1237-1244.

Research output: Contribution to journalArticleScientificpeer-review

TY - JOUR

T1 - Boron neutron capture therapy (BNCT)

T2 - Implications of neutron beam and boron compound characteristics

AU - Wheeler, Floyd

AU - Nigg, David

AU - Capala, Jacek

AU - Watkins, Peter

AU - Vroegindeweij, Corine

AU - Auterinen, Iiro

AU - Seppälä, Tiina

AU - Bleuel, Darren

PY - 1999

Y1 - 1999

N2 - The potential efficacy of boron neutron capture therapy (BNCT) for malignant glioma is a significant function of epithermal‐neutron beam biophysical characteristics as well as boron compound biodistribution characteristics. Monte Carlo analyses were performed to evaluate the relative significance of these factors on theoretical tumor control using a standard model. The existing, well‐characterized epithermal‐neutron sources at the Brookhaven Medical Research Reactor (BMRR), the Petten High Flux Reactor (HFR), and the Finnish Research Reactor (FiR‐1) were compared. Results for a realistic accelerator design by the E. O. Lawrence Berkeley National Laboratory (LBL) are also compared. Also the characteristics of the compound p‐Boronophenylaline Fructose (BPA‐F) and a hypothetical next‐generation compound were used in a comparison of the BMRR and a hypothetical improved reactor. All components of dose induced by an external epithermal‐neutron beam fall off quite rapidly with depth in tissue. Delivery of dose to greater depths is limited by the healthy‐tissue tolerance and a reduction in the hydrogen‐recoil and incident gamma dose allow for longer irradiation and greater dose at a depth. Dose at depth can also be increased with a beam that has higher neutron energy (without too high a recoil dose) and a more forward peaked angular distribution. Of the existing facilities, the FiR‐1 beam has the better quality (lower hydrogen‐recoil and incident gamma dose) and a penetrating neutron spectrum and was found to deliver a higher value of Tumor Control Probability (TCP) than other existing beams at shallow depth. The greater forwardness and penetration of the HFR the FiR‐1 at greater depths. The hypothetical reactor and accelerator beams outperform at both shallow and greater depths. In all cases, the hypothetical compound provides a significant improvement in efficacy but it is shown that the full benefit of improved compound is not realized until the neutron beam is fully optimized.

AB - The potential efficacy of boron neutron capture therapy (BNCT) for malignant glioma is a significant function of epithermal‐neutron beam biophysical characteristics as well as boron compound biodistribution characteristics. Monte Carlo analyses were performed to evaluate the relative significance of these factors on theoretical tumor control using a standard model. The existing, well‐characterized epithermal‐neutron sources at the Brookhaven Medical Research Reactor (BMRR), the Petten High Flux Reactor (HFR), and the Finnish Research Reactor (FiR‐1) were compared. Results for a realistic accelerator design by the E. O. Lawrence Berkeley National Laboratory (LBL) are also compared. Also the characteristics of the compound p‐Boronophenylaline Fructose (BPA‐F) and a hypothetical next‐generation compound were used in a comparison of the BMRR and a hypothetical improved reactor. All components of dose induced by an external epithermal‐neutron beam fall off quite rapidly with depth in tissue. Delivery of dose to greater depths is limited by the healthy‐tissue tolerance and a reduction in the hydrogen‐recoil and incident gamma dose allow for longer irradiation and greater dose at a depth. Dose at depth can also be increased with a beam that has higher neutron energy (without too high a recoil dose) and a more forward peaked angular distribution. Of the existing facilities, the FiR‐1 beam has the better quality (lower hydrogen‐recoil and incident gamma dose) and a penetrating neutron spectrum and was found to deliver a higher value of Tumor Control Probability (TCP) than other existing beams at shallow depth. The greater forwardness and penetration of the HFR the FiR‐1 at greater depths. The hypothetical reactor and accelerator beams outperform at both shallow and greater depths. In all cases, the hypothetical compound provides a significant improvement in efficacy but it is shown that the full benefit of improved compound is not realized until the neutron beam is fully optimized.

KW - BNCT neutron

KW - glioma

KW - treatment planning

U2 - 10.1118/1.598618

DO - 10.1118/1.598618

M3 - Article

VL - 26

SP - 1237

EP - 1244

JO - Medical Physics

JF - Medical Physics

SN - 0094-2405

IS - 7

ER -